CALR Allele Burden for Myeloproliferative Neoplasms
Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI)
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 260 (estimated)
- Sponsor
- University Hospital, Angers · Government
This trial is looking for adults with a specific type of blood cancer called CALR mutated myeloproliferative neoplasm. Participants will be monitored to see how their condition progresses and must provide consent to join.
You may be able to join if
- I am at least 18 years old
- I am part of the national social security system
- I have been diagnosed with CALR mutated myeloproliferative neoplasm between 2006 and 2020
- I have at least one sample available from my diagnosis or before treatment
- I have signed consent to participate
- I consent to be included in the national clinical-biological database
You may not be able to join if
- I have another active hematological disease or cancer
- I am under a legal protection scheme or unable to give consent
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityProspective study to evaluate the relevance of CALR allele burden monitoring as a molecular marker of disease progression.
Loading trial locations…